Gene therapy start-up GenSight Biologics has raised €32 million (US$41 .6 million) in a Series A funding, hinting that following on from the first European regulatory approval of a gene therapy and with an increasing volume of positive clinical data, this iconic field is now de-risked in the eyes of venture capital investors.
Read More
LONDON – Scientists are close to identifying new genes that may be linked to several eye diseases in humans, many of which cause blindness. The researchers are being guided by genes they have found in mice that, when absent, cause similar defects to those occurring in the eyes of humans who are affected by conditions such as one type of age-related macular degeneration (AMD).
Read More
S-TARget therapeutics GmbH, an Austrian start-up developing therapeutic vaccines for allergies, aims to close a €6 million (US$7.8 million) Series A funding round in the coming months.
Read More
MedDay raised €8 million (US$10.5 million) to take forward three drug development programs, two of which already have yielded promising data in small-scale human trials, in progressive forms of multiple sclerosis (MS) and in treatment-resistant forms of psychotic illness.
Read More
SHANGHAI – As the S&P 500, the Dow Jones Industrial Average and the Nasdaq Biotechnology Index close at record highs, one might think that respectable Chinese biopharmas on the New York Stock Exchange or Nasdaq would be well positioned to enjoy the benefits of such a robust stock market. In fact, many are cutting their ties. Read More
